Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b (CDw32 or Fc Gamma RII-b or CD32 or FCGR2B) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b (CDw32 or Fc Gamma RII-b or CD32 or FCGR2B) – Pipeline Review, H2 2016’, provides in depth analysis on Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b (CDw32 or Fc Gamma RII-b or CD32 or FCGR2B) targeted pipeline therapeutics.

The report provides comprehensive information on the Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b (CDw32 or Fc Gamma RII-b or CD32 or FCGR2B) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b (CDw32 or Fc Gamma RII-b or CD32 or FCGR2B) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b (CDw32 or Fc Gamma RII-b or CD32 or FCGR2B)

The report reviews Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b (CDw32 or Fc Gamma RII-b or CD32 or FCGR2B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b (CDw32 or Fc Gamma RII-b or CD32 or FCGR2B) targeted therapeutics and enlists all their major and minor projects

The report assesses Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b (CDw32 or Fc Gamma RII-b or CD32 or FCGR2B) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b (CDw32 or Fc Gamma RII-b or CD32 or FCGR2B) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b (CDw32 or Fc Gamma RII-b or CD32 or FCGR2B)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b (CDw32 or Fc Gamma RII-b or CD32 or FCGR2B) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

BioInvent International AB

MacroGenics, Inc.

Shire Plc

Xencor, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b (CDw32 or Fc Gamma RII-b or CD32 or FCGR2B) Overview 7

Therapeutics Development 8

Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b (CDw32 or Fc Gamma RII-b or CD32 or FCGR2B) - Products under Development by Stage of Development 8

Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b (CDw32 or Fc Gamma RII-b or CD32 or FCGR2B) - Products under Development by Therapy Area 9

Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b (CDw32 or Fc Gamma RII-b or CD32 or FCGR2B) - Products under Development by Indication 10

Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b (CDw32 or Fc Gamma RII-b or CD32 or FCGR2B) - Pipeline Products Glance 11

Late Stage Products 11

Early Stage Products 12

Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b (CDw32 or Fc Gamma RII-b or CD32 or FCGR2B) - Products under Development by Companies 13

Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b (CDw32 or Fc Gamma RII-b or CD32 or FCGR2B) - Products under Development by Universities/Institutes 15

Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b (CDw32 or Fc Gamma RII-b or CD32 or FCGR2B) - Therapeutics Assessment 17

Assessment by Monotherapy/Combination Products 17

Assessment by Mechanism of Action 18

Assessment by Route of Administration 20

Assessment by Molecule Type 22

Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b (CDw32 or Fc Gamma RII-b or CD32 or FCGR2B) - Companies Involved in Therapeutics Development 24

BioInvent International AB 24

MacroGenics, Inc. 25

Shire Plc 26

Xencor, Inc. 27

Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b (CDw32 or Fc Gamma RII-b or CD32 or FCGR2B) - Drug Profiles 28

BI-1206 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

MGD-010 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Monoclonal Antibodies to Agonize CD40 and FCGR2B for B-cell Lymphoma and Melanoma - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Monoclonal Antibody to Agonize CD32b for Immunology - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

SHP-652 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

SM-201 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

SM-301 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

XmAb-5871 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

XmAb-7195 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b (CDw32 or Fc Gamma RII-b or CD32 or FCGR2B) - Dormant Projects 44

Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b (CDw32 or Fc Gamma RII-b or CD32 or FCGR2B) - Featured News & Press Releases 45

Nov 13, 2016: Xencor Presents Preliminary Data from an Ongoing, Open-label, Phase 2 Study of XmAb5871 in IgG4-Related Disease (IgG4-RD) at the American College of Rheumatology 2016 Annual Meeting 45

Oct 03, 2016: Preliminary Data from the Ongoing Open-Label XmAb5871 Phase 2 Pilot Study in IgG4-Related Disease to be presented at American College of Rheumatology (ACR) 2016 Annual Meeting 46

Sep 15, 2016: Xencor Initiates Phase 1b Trial of Subcutaneous Formulation of XmAb7195 46

Jun 10, 2016: MacroGenics Presents Data from Phase 1 Study of MGD010 at Annual European Congress of Rheumatology (EULAR 2016) 47

May 18, 2016: Xencor Reports Complete Data Results from XmAb7195 Phase 1a Trial Showing Rapid Reduction of Serum IgE in High IgE Atopic Subjects at ATS 2016 International Conference 48

May 11, 2016: MacroGenics to Present MGD010 Clinical Data at EULAR 2016 49

Mar 07, 2016: Xencor Initiates Two Phase 2 Trials of XmAb5871 in IgG4-Related Disease and Systemic Lupus Erythematosus 50

Nov 09, 2015: Xencor Presents Data on XmAb5871 Program at American College of Rheumatology 2015 Annual Meeting 51

Jun 26, 2015: Xencor Provides Update on Its Lead Product XmAb-5871 And Expansion of Bispecific Oncology Pipeline at R&D Day 51

Jun 26, 2015: Xencor Provides Update on XmAb-7195 And Expansion of Bispecific Oncology Pipeline at R&D Day 52

Jun 10, 2015: Xencor Reports Complete Data Results on XmAb5871 Program at European League Against Rheumatism (EULAR) 2015 Annual Meeting 52

May 11, 2015: Xencor's XmAb 5871 Program to be Featured in Poster Presentation at European League Against Rheumatism (EULAR) 2015 Annual Meeting 54

Apr 14, 2015: Cancer Cell publishes data highlighting the potential of BioInvent’s BI-1206 to help overcome antibody drug resistance in cancer therapy 54

Mar 16, 2015: MacroGenics Initiates Phase 1 Study of MGD010 for the Treatment of Autoimmune Disorders 55

Jan 29, 2015: Xencor Reports Top-line XmAb5871 Phase 1b/2a Results Showing Promising Clinical Activity in Rheumatoid Arthritis 55

Appendix 57

Methodology 57

Coverage 57

Secondary Research 57

Primary Research 57

Expert Panel Validation 57

Contact Us 57

Disclaimer 58

List of Tables

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Products under Development by Companies, H2 2016 14

Number of Products under Investigation by Universities/Institutes, H2 2016 15

Products under Investigation by Universities/Institutes, H2 2016 16

Assessment by Monotherapy/Combination Products, H2 2016 17

Number of Products by Stage and Mechanism of Action, H2 2016 19

Number of Products by Stage and Route of Administration, H2 2016 21

Number of Products by Stage and Molecule Type, H2 2016 23

Pipeline by BioInvent International AB, H2 2016 24

Pipeline by MacroGenics, Inc., H2 2016 25

Pipeline by Shire Plc, H2 2016 26

Pipeline by Xencor, Inc., H2 2016 27

Dormant Projects, H2 2016 44

List of Figures

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Top 10 Indication, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy/Combination Products, H2 2016 17

Number of Products by Mechanism of Actions, H2 2016 18

Number of Products by Stage and Mechanism of Actions, H2 2016 18

Number of Products by Routes of Administration, H2 2016 20

Number of Products by Stage and Routes of Administration, H2 2016 20

Number of Products by Molecule Types, H2 2016 22

Number of Products by Stage and Molecule Type, H2 2016 22

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports